Comparative Pharmacology
Head-to-head clinical analysis: BROVANA versus THEOLAIR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BROVANA versus THEOLAIR.
BROVANA vs THEOLAIR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
BROVANA (arformoterol tartrate) is a long-acting beta2-adrenergic agonist (LABA). It stimulates intracellular adenyl cyclase, increasing cyclic AMP levels, leading to relaxation of bronchial smooth muscle and inhibition of mast cell mediator release.
Theophylline, the active ingredient in THEOLAIR, is a phosphodiesterase inhibitor that increases intracellular cAMP levels, leading to bronchodilation via smooth muscle relaxation. It also has anti-inflammatory effects and may enhance diaphragmatic contractility.
15 mcg (2 mL) by nebulization twice daily, not to exceed 30 mcg/day.
Initial dose: 300 mg orally every 8-12 hours; titrate based on serum theophylline levels to achieve 5-15 mcg/mL. Maintenance: 400-600 mg/day in divided doses.
None Documented
None Documented
Terminal elimination half-life: approximately 26 hours (range 22–30 hours) in healthy adults; prolonged in hepatic impairment (up to 50% increase).
Adults: 3-8 hours (mean 5.5); children: 1.5-5 hours; increased in hepatic cirrhosis, heart failure, and COPD; decreased in smokers
Primarily renal (60% unchanged drug); remainder via biliary/fecal (approximately 20%) and metabolic transformation.
Renal (10% unchanged); hepatic metabolism (90%) with metabolites excreted in urine
Category C
Category C
Bronchodilator
Bronchodilator